Leaders in Pharmaceutical Business Intelligence (LPBI) Group

World Medical Innovation Forum, June 12 – June 14, 2023 The Westin Boston Seaport District organized by Mass General Brigham (MGB)

Reporter: Aviva Lev-Ari, PhD, RN

FRONTIER OF MEDICINE, HEALTHCARE AND BIOTECH WAS PRESENTED AT World Medical Innovation Forum, June 12 – June 14, 2023 The Westin Boston Seaport District organized by Mass General Brigham (MGB) https://pharmaceuticalintelligence.com/2023/06/25/world-medical-innovation-forum-june-12-june-14-2023-the-westin-boston-seaport-district-organized-by-mass-general-brigham-mgb/ via @pharma_BI @AVIVA1950 #WMIF @MGBInnovation

Aviva Lev-Ari, PhD, RN

Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0

 

Since 2015, I am attending the World Medical Innovation Forum (WMIF) on a granted Press Pass covering the event in Real Time.

In 2019, I was ranked #3 Influencer

Top 3 Ranked by Betweenness Centrality in Top 10 Influencers #WMIF19 @phsinnovation @evankirstel @aviva1950 – Twitter Analytics by NodeXL http://bit.ly/2KB6cPN  for #WMIF19 by @PHSInnovation  at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019

www.worldmedicalinnovation.org

https://pharmaceuticalintelligence.com/2019/04/11/top-3-ranked-by-betweenness-centrality-in-top-10-influencers-wmif19-phsinnovation-evankirstel-aviva1950-tweeter-analytics-by-nodexl-http-bit-ly-2kb6cpn-for-wmif19-by-phs/

NodeXL http://bit.ly/2KB6cPN

@symplur‘s #Healthcare Hashtags  – Twitter Analytics published for http://bit.ly/WMIF19 

In 2023, I was registered as Press for the event, World Medical Innovation Forum, June 12 – June 14, 2023

Due to an emergency I could not attend in-person.

Below, based on all the videos posted at

https://www.youtube.com/c/WorldMedicalInnovationForum

I am adding key concepts Of Note:

World Medical Innovation Forum

2023 FIRST LOOK

 

Mark Albers, MD, PhD

Frank Wilkens Jr and Family Endowed Scholar in AD Research, MGH; Assistant Professor of Neurology, HMS

TYK2 as a novel therapeutic target in a subset of Alzheimer’s Disease with neuroinflammation

• Predictive Biomarkers for ALS & AD
• Genetic validation: TYK2 – NADALS Basket Trial

 

Yakeel Quiroz, PhD

Director, Familial Dementia Neuroimaging Lab and Director, Multicultural Alzheimer’s Prevention Program, MGH; Paul B. and Sandra M. Edgerley MGH Research Scholar; Associate Professor, HMS

Untangling the role of rare genetic variant in protection against Alzheimer’s disease: From biomarkers to novel therapeutic targets

·      Unmet needs of AD

·      Familial AD research: sporadic late onset +65

·      COLBOS Extreme – Protection against Dementia

·      Regulation of amyloid formation: Amyloid Beta aggregation & uptake

·      Neuronal Tau – mutation on Reelin gene

·      Bind to heparin

·      Reduce Tau phosphorylation

 

Tanya Mayadas, PhD

Senior Staff Scientist, BWH; Professor of Pathology, HMS Targeting neutrophils for T cell-mediated anti-tumor immunotherapy

Targeting neutrophils for T cell-mediated anti-tumor immunotherapy

• Dendritic cells lack robust anti-tumor
• Neutrophil CD16B with Antigen to generate APCs
• AAC increases T cells and neutral killer (NK) cell infiltration
• AAC enhances anti PD-1 increases activation and accumulation of memory TSCM and TRM cells
• Translation – AAC combination therapy

 

Synho Do, PhD

Director, Lab of Medical Imaging and Computation, Mass General Brigham; Assistant Professor, HMS

SafeAI: Live Error-free or Die

• AI Classifier
• AI algorithms effective errors – accountability for AI mistakes
• Error-free in normal cases vs in all cases
• Scalability and large-scale data throughput
• Continuous Learning AI: Auto-label open DBs
• Repurposing AI: from traditional AI to SafeAI

 

Tatjana Jakobs, MD

Associate Scientist, Schepens Eye Research Institute of Mass Eye and Ear; Associate Professor of Ophthalmology, HMS

Astrocyte-derived SPP1 prevents age and glaucoma-related loss of vision

• Age and glaucoma
• Mining astrocytes for neuroprotective factors
• Spp1 is expressed in response to optic nerve damage – is neuroprotective
• Overexpression of Spp1 via AAV2
• Visual acuity in glaucoma
• Retinal ganglion cells- Spp1 as a noval target

 

Russell Jenkins, MD, PhD

Investigator, Center for Cancer Research, MGH; Assistant Professor of Medicine, HMS

Evaluating Novel Cancer Therapeutic Strategies Using Living Tumor Biopsies

• Matastatic cancer (melanoma) cured with immunotherapy
• PD-1 and PDL-1 pathways – Solid tumors
• Clinical Trial landscape is very complex
• Combination therapy Trials – Human tumor immunity: Check inhibitors -pus antiPD-1 – functional precision cancer medicine
• Testing across cancer types & stages
• Deprioritized ineffective strategies
• ROCHE leads the way
• PDOTS tumor-immune interactions

 

Clotilde Lagier-Tourenne, MD, PhD

Araminta Broch-Healey Endowed Chair in ALS, MGH; Associate Professor of Neurology, HMS

Targeting disruption of stathmin-2 in neurodegenerative diseases

• ALS and FTD (Frontaltemporal Dementia): Overlapping neurodegenerative diseases
• TDP-43: an RNA binding protein in abnormal slpicing of stathmin-2 (STMN2)
• STMN2 – neuromuscular junctions and axonal regeneration
• Statin-mediated increase in STMN2 RNA with neurite extension– compound that restore STMN2 in neurodegenerative disease

 

Kerry Ressler, MD, PhD

Chief Scientific Officer, McLean Hospital; Professor of Psychiatry, HMS

Preventing post-traumatic stress disorder: Novel pharmacological approaches based on the neuroscience of fear

• Two drugs for PTSD – no biomarkers known
• Neuroscience – fear: amygdala biology of trauma
• Memory of fear – Trauma consolidation: car crush
• AURORA study
• Amygdala reactivity 3 month and 12 month later – efficacy of NKB-expressing cells – antagonismachieve fear expression reduced
• Predictive analytics to prevent sequela of PTSD
• Atomwise – new compounds

 

Fabrisia Ambrosio, PhD

Atlantic Charter Director of the Discovery Center for Musculoskeletal Recovery, Schoen Adams Research Institute, Spaulding Rehabilitation Hospital; Faculty, HMS

Extracellular vesicle engineering to counteract age-related cognitive declines

• Age and exercise have circulating rejuvenating effects
• Lifespan: decline physical and cognitive
• Extracellular Vesicles (EV): information exchange reprogram distal cells
• EV cross the BBB: functional memory, circulatory contribution
• CNS application to benefit from research on EV – evaluate cognitive outcomes
• Molecules: Klotin effect in the aging brain
• Molecular cargo: optimize cargo engineering, dosing study and Kinetics

 

Li Chai, MD

Pathologist and Principal Investigator, BWH; Associate Professor of Pathology, HMS

Novel mechanism and compound targeting oncogenic transcription factor SALL4 in cancer

• Transcription factors SALL4 – a “fetal-oncoprotein” in the liver – is present in wild variety of tumors
• SALL4 knockout mice are resistant to tumor formation
• Mechanism: MYC and PTEN known to drive cancer formation
• Liver cancer HCC: high incidence globally, high mortality, no effective therapy
• SALL4 target viability: CP1, a non-IMiD (IP protected) small molecule SALL4 degrader reduceing tumor growth in vivo — >> apoptosis

 

Angela Shen, MD / Marcela Maus, MD, PhD

Original Presenter: Marcela Maus, MD, PhD Director, Cellular Immunotherapy, MGH; Associate Professor, HMS Video Presenter: Angela Shen, MD Vice President, Strategic Innovation Leaders, MGB Innovation

Novel CAR-T cells engineered to overcome obstacles observed in the clinic

• CAR-T next generation genetically-modified (CAR) T in patients with cancer and other diseases
• New targets – CD37 and CD70 – B & T cell lymphoma, AML
• TACI/BCMA – multiple myeloma
• Target multiple targets – CD79b/CD19 – B cell lymphoma
• CRISPR – solid tumors, novel proof of concept POC
• Allo and auto rejection – Cloaking
• CAR-TEAM [T cell Engaging Antibody Molecule]

 

Ralph Mazitschek, PhD

Ralph Mazitschek, PhD Principal Investigator, MGH; Assistant Professor, HMS

Unlocking aminoacyl-tRNA-synthetases as novel drug targets for first-in-class therapeutics

• Aminoacyl tRNA-Syntherases (aaRSs) as grug target after the biology is known
• Human aaRSspoised for small moledule inhibitors
• No drug no progress no interest
• Current aaRS inhibitor discovery & development: high throughput screening & medicinal chemistry campaign
• Human prolyl-tRNA synthease: NCP26 targets cancer cells by Inhibiting multiple myeloma growth in vitro and in vivo
• Many aaRS Isoforms lessons from Kinase Inhibitors

2023 WMIF | Disruptive Dozen

https://www.youtube.com/watch?v=HtKbvhzWHKI

 

2023 WMIF |The Dr. Is In

https://www.youtube.com/playlist?list=PLPkoxDmLtWIqIgwLDYCygexlIDuqBKb1d

<iframe width=”560″ height=”315″ src=”https://www.youtube.com/embed/videoseries?list=PLPkoxDmLtWIqIgwLDYCygexlIDuqBKb1d&#8221; title=”YouTube video player” frameborder=”0″ allow=”accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share” allowfullscreen></iframe>